According to the most recent research by XploreMR, the global sinusitis treatment market revenues were ~ US$ 6.9 Bn in 2018. The report opines that the sinusitis treatment approach identified with acute and chronic sinusitis is changing, and the treatment methods are resulting in less morbidity rates, around the world. Individuals who have sensitivities, asthma, and auxiliary blockages in the nose or sinuses, or individuals with frail invulnerable frameworks opt for sinusitis treatment, says research.

The sinusitis treatment market has been divided on the basis of indication, into acute and chronic sinusitis. The use of different drug class has played a very important role in the management of sinusitis. Topical corticosteroid therapy and high-volume saline irrigation continue to be the cornerstone to medical therapy, whereas the use of systemic corticosteroids and antibiotics depends upon the chronic rhinosinusitis phenotype and the presence of acute exacerbation. Leukotriene inhibitors may play a role, especially in patients with coexisting asthma. The choice of treatment for sinusitis normally start with topical nasal steroids, along with Antibiotics, anti-histamines, NSAIDs and Expectorants.

Sinusitis treatment is carried out by symptomatic treatment with antibiotics, analgesics, decongestants, and saline irrigation. Sinusitis treatment comprises of different indication types, drug classes, and distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies. It is anticipated that hospital pharmacies will be among the prominent distribution channels in the sinusitis treatment market with a significant global market share.

The market growth of the leading distribution channels in the sinusitis treatment market can be primarily attributed to an increase in the prevalence rate of sinusitis, increase in the available treatment options, increase in the sales OTC products, increase in predisposing factors such as environmental factors, rising prevalence of asthma, primary immune deficiency, and anatomical factors, which are contributing to growth in the patient pool suffering from sinusitis.

Key Market Participants Eyeing FDA Approvals

Major players in the sinusitis treatment market are focusing on new product approvals, launch of generic drugs, and increasing collaboration to expand their reach. Continuous investments in research and development have resulted in FDA approval for the treatment of nasal polyps accompanied by chronic sinusitis. To remain competitive in the sinusitis treatment market, several players are engaged in acquisitions, collaborations, partnerships, and expansions. Key players in the sinusitis treatment market compete based on the pricing of drug class and types of indications.

The global sinusitis treatment market report offers a comprehensive taxonomy of the sinusitis treatment market based on the indication type, drug class, distribution channel, and region. Based on the indication type, the global sinusitis treatment market is segmented into acute sinusitis and chronic sinusitis. Based on drug class, the global sinusitis treatment market is segmented into antibiotics, corticosteroids, anti-histamines, NSAIDs, saline irrigations, and leukotriene receptor antagonist. Antibiotics are further divided into beta lactamase inhibitors, macrolides, quinolones, tetracycline, and cephalosporin.

The sinusitis treatment market report tracks some of the key companies operating in the global sinusitis treatment market, which include Sanofi, Bayer AG, Abbott Laboratories, Eli Lily and Company, Merck & Co., Inc., AstraZeneca Plc, Dr. Reddy’s Lab, Novartis AG, Sun Pharmaceuticals, and Pfizer Inc.

This report examines the growth of the global sinusitis treatment market during a 10-year projection period, 2019-2029. A healthy ~6.5% CAGR has been estimated for market growth through 2029.